Partial Onset Seizures In Adults Therapeutics
1. Aptiom patent expiration
Treatment: Treatment of partial-onset seizures in a patient suffering from or susceptible to absence seizures; Treatment of partial-onset seizures; Treatment of partial-onset seizures in patients with epilepsy w...
APTIOM's oppositions filed in EPO
Can you believe APTIOM received compensation for the extended wait time during the regulatory approval process?
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US5753646 | SUMITOMO PHARMA AM | Substituted dihydrodibenzo/b,f/azepines, method of their preparation, their use in the treatment of some central nervous system disorders, and pharmaceutical compositions containing them |
Jun, 2021
(4 years ago) | |
| US9206135 | SUMITOMO PHARMA AM | Asymmetric catalytic reduction of oxcarbazepine |
Apr, 2026
(3 months from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9750747 | SUMITOMO PHARMA AM | Treatments involving eslicarbazepine acetate or eslicarbazepine |
Aug, 2032
(6 years from now) | |
| US10702536 | SUMITOMO PHARMA AM | Methods of treatment of partial onset seizures using eslicarbazepine acetate |
May, 2025
(8 months ago) | |
| US9763954 | SUMITOMO PHARMA AM | Therapeutical uses of eslicarbazepine |
Sep, 2028
(2 years from now) | |
| US10695354 | SUMITOMO PHARMA AM | Methods of treatment of partial onset seizures using eslicarbazepine acetate |
May, 2025
(8 months ago) | |
| US10675287 | SUMITOMO PHARMA AM | Methods of treatment of partial onset seizures using eslicarbazepine acetate |
May, 2025
(8 months ago) | |
| US11364247 | SUMITOMO PHARMA AM | Methods of treatment of partial onset seizures using eslicarbazepine acetate |
May, 2025
(8 months ago) | |
| US9643929 | SUMITOMO PHARMA AM | Asymmetric catalytic reduction of oxcarbazepine |
Apr, 2026
(3 months from now) | |
| US9566244 | SUMITOMO PHARMA AM | Pharmaceutical composition comprising licarbazepine acetate |
Oct, 2028
(2 years from now) | |
| US10912781 | SUMITOMO PHARMA AM | Pharmaceutical composition comprising licarbazepine acetate |
Oct, 2028
(2 years from now) | |
| US8372431 | SUMITOMO PHARMA AM | Pharmaceutical composition comprising licarbazepine acetate |
Apr, 2030
(4 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Dosing Schedule(D-150) | Aug 27, 2018 |
| New Indication(I-715) | Aug 27, 2018 |
| New Chemical Entity Exclusivity(NCE) | Nov 08, 2018 |
Drugs and Companies using ESLICARBAZEPINE ACETATE ingredient
NCE-1 date: 08 November, 2017
Market Authorisation Date: 08 November, 2013
Dosage: TABLET
How can I launch a generic of APTIOM before it's drug patent expiration?
More Information on Dosage
APTIOM family patents
2. Keppra patent expiration
Treatment: NA
KEPPRA's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8802142 | UCB INC | Pharmaceutical compositions comprising levetiracetam and process for their preparation |
Jun, 2031
(5 years from now) | |
|
US8802142 (Pediatric) | UCB INC | Pharmaceutical compositions comprising levetiracetam and process for their preparation |
Dec, 2031
(5 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Patient Population(NPP) | Dec 16, 2014 |
| Pediatric Exclusivity(PED) | Jun 16, 2015 |
Drugs and Companies using LEVETIRACETAM ingredient
Market Authorisation Date: 06 January, 2006
Dosage: TABLET
How can I launch a generic of KEPPRA before it's drug patent expiration?
More Information on Dosage
KEPPRA family patents
3. Vimpat patent
expiration
Treatment: Method of treating, as adjunctive therapy, partial-onset seizures in a patient with epilepsy aged 17 years and older; Method of treating, as adjunctive therapy, partial-onset seizures in a patient wit...
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5654301 | UCB INC | Amino acid derivative anticonvulsant |
Aug, 2014
(11 years ago) | |
| USRE38551 | UCB INC | Anticonvulsant enantiomeric amino acid derivatives |
Mar, 2022
(3 years ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Oct 28, 2013 |
| New Dosing Schedule(D-143) | Aug 29, 2017 |
| New Dosing Schedule(D-144) | Aug 29, 2017 |
| New Indication(I-696) | Aug 29, 2017 |
| M(M-217) | Nov 03, 2020 |
| New Indication(I-878) | Nov 16, 2023 |
| New Patient Population(NPP) | Oct 14, 2024 |
| New Dosing Schedule(D-188) | Apr 28, 2026 |
Drugs and Companies using LACOSAMIDE ingredient
NCE-1 date: 28 October, 2012
Market Authorisation Date: 28 October, 2008
Dosage: TABLET; SOLUTION
How can I launch a generic of VIMPAT before it's drug patent expiration?
More Information on Dosage
VIMPAT family patents
4. Xcopri patent expiration
Treatment: Co-administration of cenobamate with phenobarbital and/or phenytoin for the treatment of partial onset seizures
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7598279 | SK LIFE | Neurotherapeutic azole compounds |
Oct, 2032
(6 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11654133 | SK LIFE | Use of [(1R)-1-(2-chlorophenyl)-2-(tetrazol-2-yl)ethyl] carbamate in combination therapy |
Jun, 2039
(13 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Mar 10, 2025 |
Drugs and Companies using CENOBAMATE ingredient
NCE-1 date: 10 March, 2024
Market Authorisation Date: 10 March, 2020
Dosage: TABLET
More Information on Dosage
XCOPRI family patents